Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar with Platinum-Based Chemotherapy in Advanced NSCLC
NCT05574998Phase 2Unknown
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Feb 2021
- Primary completion
- Feb 2024
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of endostar in non-small cell lung cancer (NSCLC), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: Progression-Free Survival at 36 months. Status: unknown.
02
Drugs
endostar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05574998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05574998.